Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD highlight the common practice in many community settings of treating inflammatory bowel disease with corticosteroids, with or without 5-aminosalicylic acid, and cycling patients through this regimen for prolonged periods, while emphasizing the significant impact and toxicities associated with this treatment approach.
In many community practices, IBD is treated with corticosteroids with or without 5-ASA, and patients are cycled through this regimen for a long time. How does this approach impact long-term patient outcomes?